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Antiretroviral Drug Levels and Interactions 
Affect Lipid, Lipoprotein, and Glucose Metabolism 
in HIV-1 Seronegative Subjects: A Pharmacokinetic-
Pharmacodynamic Analysis
SUSAN L. ROSENKRANZ, Ph.D.,1 KEVIN E. YARASHESKI, Ph.D.,2
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ABSTRACT
Background: HIV-infected patients treated with antiretroviral medications (ARVs) develop
undesirable changes in lipid and glucose metabolism that mimic the metabolic syndrome and
may be proatherogenic. Antiretroviral drug levels and their interactions may contribute to
these metabolic alterations.
Methods: Fifty six HIV-seronegative adults were enrolled in an open-label, randomized,
pharmacokinetic interaction study, and received a nonnucleoside reverse transcriptase in-
hibitor (efavirenz on days 1–21) plus a protease inhibitor (PI; amprenavir on days 11–21), with
a second PI on days 15-21 (saquinavir, nelfinavir, indinavir, or ritonavir). Fasting triglycerides,
total LDL- and HDL-cholesterol, glucose, insulin, and C-peptide levels were measured on
days 0, 14, 21, and 2–3 weeks after discontinuing drugs. Regression models were used to es-
timate changes in these parameters and associations between these changes and circulating
levels of study drugs.
Results: Short-term efavirenz and amprenavir administration significantly increased cho-
lesterol, triglycerides, and glucose levels. Addition of a second protease inhibitor further in-
creased triglycerides, total and LDL-cholesterol levels. Higher amprenavir levels predicted
larger increases in triglycerides, total, and LDL-cholesterol. Two weeks after all study drugs
were stopped, total, LDL-, and HDL-cholesterol remained elevated above baseline.
Conclusions: ARV regimens that include a nonnucleoside reverse transcriptase inhibitor
plus single or boosted PIs are becoming more common, but the pharmacodynamic interac-
tions associated with these regimens can result in persistent, undesirable alterations in serum
lipid/lipoprotein levels. Additional pharmacodynamic studies are needed to examine the
metabolic effects of ritonavir-boosted regimens, with and without efavirenz.
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INTRODUCTION
FORTY TO 60% OF HIV-INFECTED PATIENTS treatedwith antiretroviral medications (ARVs) expe-
rience undesirable metabolic, endocrine, and
body composition changes, including insulin re-
sistance, dyslipidemia, elevated diastolic blood
pressure, visceral adiposity and/or peripheral
lipoatrophy, elevated serum biomarkers for 
prothrombotic events, and chronic inflamma-
tion.1–10 These are components of the car-
diometabolic syndrome, and threaten to increase
cardiovascular events in HIV-infected peo-
ple,3,4,11–26 but little is known about how ARV
drug levels and interactions contribute to these
metabolic alterations.
Many factors contribute to metabolic alter-
ations in HIV-infected people treated with ARVs:
HIV-1 infection, direct and indirect actions of
ARVs on substrate metabolism, genetics, cy-
tokines, nutrition, physical inactivity, behavior,
gender, and age. Most studies have focused on
HIV-protease inhibitors (PIs) as causative factors.
In healthy HIV-seronegative subjects, short-term
exposure (4 weeks) to the PI indinavir impaired
peripheral and hepatic insulin sensitivity with-
out affecting lipid/lipoproteins,27,28 whereas
short-term lopinavir/ritonavir exposure im-
paired insulin sensitivity,29 and increased serum
triglycerides (TG), very low-density lipoprotein-
cholesterol (VLDL-c), and free fatty acid levels
without changing low- or high-density lipopro-
tein-cholesterol (LDL-c or HDL-c).30 Two-week
exposure to escalating doses of ritonavir in-
creased TG and VLDL-c (but not LDL-c), and re-
duced HDL-c in HIV-negative subjects.31 Five
days of atazanavir exposure, however, did not af-
fect insulin sensitivity.29 In general, indinavir-
containing regimens tend to alter glucose me-
tabolism, while ritonavir-containing regimens
tend to prompt dyslipidemia. These studies are
limited because individual PIs were adminis-
tered. In current clinical practice, regimens in-
clude dual- or boosted-PIs plus other ARV drug
classes (nucleoside and nonnucleoside reverse
transcriptase inhibitors, NRTI, NNRTI). Little is
known about the direct pharmacokinetic interac-
tions among these drug combinations and their
effects on serum lipid and glucose parameters.
Large HIV-infected cohorts corroborate
these findings.32,33 PI-containing regimens (es-
pecially ritonavir) were associated with higher
TG and total cholesterol (TC) levels than indi-
navir-containing regimens, or non-PI-contain-
ing regimens. NNRTI-containing regimens
(efavirenz, nevirapine) were associated with
higher TC and LDL-c values than those in
ARV-naive patients. Efavirenz- and nevirap-
ine-containing regimens have been associated
with increments in HDL-c levels,33–36 despite
their undesirable effects on serum TG and TC
levels. Nevirapine-containing ARV regimens
have been associated with larger increases in
HDL-c and decreases in the ratio of TC–HDL-c
(TCHC) than efavirenz-containing regimens.37
Taken together, these findings suggest that
some PI-to-NNRTI substitutions and PI-spar-
ing regimens may be associated with more fa-
vorable lipid profiles in HIV-infected people.
We hypothesized that alterations in fasting
lipid/lipoprotein and glucose metabolism are
caused by combined actions of efavirenz
(NNRTI) and amprenavir (PI), compounded by
the addition of a second PI through pharma-
cokinetic (PK) drug interactions, and that
markers of lipid and glucose metabolism
would be related to plasma efavirenz and am-
prenavir concentrations. To test these hy-
potheses, fasting serum lipid/lipoprotein, glu-
cose, insulin, and C-peptide levels and drug
concentrations were quantified during a phar-
macokinetic interaction study conducted in
healthy, HIV-1-seronegative men and women
exposed to a short course of efavirenz plus am-
prenavir, followed by the addition of a second




ACTG A5043 was an open-label, randomized
study. Subjects received a single, oral dose of
amprenavir 600 mg alone on day 0, efavirenz
600 mg daily alone on days 1-10, amprenavir
600 mg once every 12 hours (q12h) plus
efavirenz 600 mg q24h on days 11-14, and
efavirenz plus amprenavir with or without ad-
ministration of a second, randomly assigned PI
on days 15–21 (Figure 1). The second PI was
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M M M M
Amprenavir AUCs
(ug*h/mL)
All arms All arms C S N I R
Median= 8 3.9 4.4 , 4.6 , 14.1 , 14.2 , 32.5
Efavirenz AUCs
(ug*h/mL)
All arms C S N I R
Median= 39.8 36.9 , 37.9 , 42.7 , 33.1 , 41.6
FIG. 1. Top panel: Schedule of ACTG A5043 study drug administration and laboratory evaluations (PK, intensive
pharmacokinetic sampling conducted; M, fasting metabolic samples collected). Middle panel: Summary of ampre-
navir PK findings. Top of bar and number indicate median AUC. On days 0 and 14, all arms are combined. On day
21, arms are presented separately: C, control; S, saquinavir; N, nelfinavir; I, indinavir; and R, ritonavir. Bottom panel:
Summary of efavirenz PK findings.
saquinavir soft gelatin capsules 1600 mg q12h,
nelfinavir 1250 mg q12h, indinavir 1200 mg
q12h, ritonavir 100 mg q12h, or none (control
arm). One objective was to compare the PK of
amprenavir when taken alone, with efavirenz,
and with efavirenz plus a second PI; and the
PK of efavirenz taken with amprenavir, with
and without a second PI. A second objective
was to examine the effects of these drug com-
binations/interactions on fasting glucose and
lipid metabolism.
Inclusion criteria included HIV-1-seronega-
tive, 18–65 yr old, male or female,  50 kg and
within 20% of ideal body weight, of stable
health over the preceding 6 months, liver func-
tion tests 1.25  upper limit of normal
(ULN), and fasting TC and TG  200 mg/dL.
Other study details are described elsewhere.38
The purpose, risks, benefits, and confidential-
ity concerns were explained to each volunteer.
All eligible volunteers signed an IRB-approved
informed consent document.
On days 0 (baseline, prior to exposure to any
study drug), 14, and 21, and 2–3 weeks after
discontinuation of all study drugs (day 42),
fasting blood samples (7.5–16.5h from food/
drink intake) were collected in the morning,
prior to administering study drug. Samples
were stored at 20°C and analyzed for TG, TC,
HDL-c, glucose (GLU), insulin (INS), and C-
peptide (CPEP) levels in batches when the
study ended in site-designated laboratories.
Subject height and weight were measured on
day 0; weight was also measured on days 14,
21, and 42. The following measures were cal-
culated: LDL-c (TC-[HDL-c  {TG  5}]), the
ratio of TC to HDL-c (TCHC), the homeostasis
model assessment of insulin resistance
(HOMA  fasting GLU [mM]  fasting INS
[U/mL]/22.5),39 and body mass index
(BMI  weight [kg]/height [m2]). For 5 of 222
subject-day occasions (2%), GLU, INS, CPEP,
and TG values were clearly nonfasting, and
were excluded from analysis. PK sampling was
conducted on days 0, 14 and 21. Compliance
was assessed by pill counts and self-report.
Subjects were excluded from analyses if 1, 2
or 6 doses were missed in the 48h, 72h or 14
days, respectively, prior to PK/metabolic spec-
imen collection. For a given lipid/glucose mea-
sure, a subject’s data were included if the sub-
ject contributed valid values on 2 occasions.
NCEP ATP III guidelines for the metabolic syn-
drome40 were used to classify fasting TC, LDL-
c, HDL-c, and TG values. Fasting GLU
	110mg/dL and INS levels 	15U/mL were
considered elevated.
Statistical analysis
Baseline values. Descriptive statistics are re-
ported by study day. ANOVA models were
used to evaluate baseline differences in meta-
bolic parameters, weight, height, and BMI by
treatment arm and race/ethnicity (African-
American/nonHispanic vs others).
Changes over time. We focused on three com-
parisons: (1) day 14 vs. baseline, i.e., how meta-
bolic parameters changed after 14 days of
efavirenz and 3 days of amprenavir exposure;
(2) day 21 vs. 14, i.e., how parameters changed
after 7 additional days of efavirenz and am-
prenavir plus (in four arms) exposure to a sec-
ond PI; and (3) day 42 vs. baseline, i.e., meta-
bolic parameters 2–3 weeks after discontinuing
all medications. A repeated-measures model
was fit to available data for a given measure,
consisting of an overall mean (day 0 values);
additive fixed effects for days 14, 21 and 42; and
a random intercept for each subject.
For a given outcome, if day was statistically
significant, least-squares means of changes
over time were reported, and considered sta-
tistically significant if associated 95% CIs ex-
cluded the value zero. For outcomes where day
was significant, additional differences between
PIs (arms) on day 21 were evaluated. Where
day was not significant, indicators for pres-
ence/absence of each second PI were evaluated
as the only model covariates.
Relationships between ARV PK parameters and
metabolic alterations. Compared to amprenavir
areas under the curve (AUCs) when taken
alone (day 0), AUCs of amprenavir taken with
efavirenz (day 14) were smaller, and taken with
efavirenz and a second PI were more variable38
(Figure 1). On day 21, amprenavir AUCs were
highest for subjects taking ritonavir and lowest
on the control and saquinavir arms.38 Regres-
sion models were used to estimate effects of
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day 14 amprenavir AUC and baseline meta-
bolic value on metabolic changes at day 14. If
amprenavir AUC was a significant explanatory
variable, the regression equation was reported,
along with predicted metabolic outcomes over
a range of possible amprenavir exposures. Ef-
fects of day 21 amprenavir AUCs on day 21
metabolic changes, and of efavirenz AUCs on
both days, were similarly assessed.
Deviance statistic p-values41  0.05 were
considered significant. Analyses were ex-
ploratory; therefore, no adjustments were
made for multiple comparisons.
RESULTS
Of 82 subjects enrolled into the study and re-
ceiving some study drug, 56 took drug per pro-
tocol, had valid results for at least one meta-
bolic outcome, and were therefore included in
analyses. Numbers of subjects included in the
analyses relative to the number randomized to
each second PI arm were as follows: control
11/16, saquinavir 10/16, nelfinavir 12/18, in-
dinavir 13/19, and ritonavir 10/16. Baseline
weight and BMI did not differ significantly by
arm. Body weight fluctuations over the 42 days
were minor, ranging from 6% to 8% (
5
kg). There were no differences in body weight
or BMI by study day. Baseline metabolic out-
comes did not differ by race/ethnicity (African-
American/non-Hispanic vs. other).
Baseline lipid, lipoprotein, and glucose pa-
rameters are given in Table 1. TC and LDL-c
were within the normal range at baseline for all
subjects. At baseline, 18% of subjects had TG
above the NCEP threshold (150 mg/dL); 33%
of 49 men and 0% of the 2 women had HDL-c
below their respective thresholds of 40 and 50
mg/dL. Baseline CPEP was lowest in subjects
randomized to ritonavir and highest in those
assigned to the control arm. Three of the 5
metabolic syndrome components were quanti-
fied in this study (glucose 	 100 mg/dL, HDL-
cholesterol  40 mg/dL [50 mg/dL for wo-
men] and triglycerides 	 150 mg/dL). No
subject met all three criteria on any study day.
Significant differences among days were
seen for cholesterol measures, TG, GLU and
INS (Table 2). In comparing day 14 vs. day 0,
exposure to efavirenz and amprenavir signifi-
cantly increased TC (least-squares estimate
[LSE] of change was 15 mg/dL), LDL-c (10
mg/dL), HDL-c (2.5 mg/dL), TG (16 mg/dL),
and GLU (2.3 mg/dL). TCHC and INS changes
did not differ from zero. An additional 7 days
of exposure to efavirenz plus amprenavir (day
21 vs. day 14), with or without a second PI
(pooling arms), increased TC (LSE change from
day 14, 13 mg/dL), LDL- (9 mg/dL), TCHC
(0.37) and TG (18 mg/dL). HDL-c, GLU, and
INS were not changed further from day 14.
Overall, comparing day 42 vs. day 0, ARV ex-
posure was discontinued, but TC remained sig-
nificantly elevated over baseline (29 mg/dL),
as did LDL-c (20 mg/dL), HDL-c (7.0 mg/dL),
and INS (1.0 U/mL). TCHC, TG, and GLU
values, however, were restored to near baseline
at this follow-up visit. Day 42 changes were not
associated with length of time since drug dis-
continuation (actual range 1-5 weeks).
On day 21, only TCHC differed with second
PI. TCHC increases on the nelfinavir and con-
trol arms were larger than increases on the
other arms. HOMA and CPEP values did not
differ by day, nor by second PIs.
Higher amprenavir AUCs on day 14 were as-
sociated with larger TCHC, TG, and CPEP 
elevations above baseline (Table 3). A regres-
sion equation was derived to predict TG incre-
ments for a given amprenavir AUC on day 14:
[27.45  (0.34  baseline TG)  (5.12  am-
prenavir AUC)]. For a subject with baseline
TG  79.5 mg/dL (median), an amprenavir
AUC of 4.0 or 8.0 g/mL would be predicted
to increase TG by 21 or 41 mg/dL, respectively.
Larger amprenavir AUCs also predicted
smaller increases in HDL-c on day 14. On day
14, larger efavirenz AUCs were associated with
larger HDL-c increases and smaller TG in-
creases.
DISCUSSION
In HIV-seronegative subjects, short-term ex-
posure to the NNRTI efavirenz plus the PI am-
prenavir increased total- and LDL-cholesterol
levels 10% above baseline. Subsequent expo-
sure to a second PI (saquinavir, nelfinavir, in-
dinavir, or ritonavir) further increased total-
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and LDL-cholesterol levels (20% above base-
line). Several healthy normal subjects devel-
oped components of the cardiometabolic syn-
drome: 29% of men had HDL-c 40 mg/dL,
23% of subjects had TG 	 150 mg/dL, and 6%
of subjects had TC 	240 mg/dL on day 21.
(HDL-c was above 50 mg/dL for the one wo-
man with available data.) Of note, HDL-c in-
creased after 14 days of efavirenz/amprenavir,
but unlike TC, did not rise further after intro-
duction of a second PI; hence TCHC was ele-
vated only on day 21. Total-, LDL-, and HDL-
c remained elevated above baseline 1–5 weeks
after discontinuing all medications. These find-
ings confirm that, even in healthy, normolipi-
demic people not infected with HIV, short-term
exposure to efavirenz plus one and two PIs can
rapidly induce alterations in fasting lipid and
ROSENKRANZ ET AL.168





parameters N Day Mean SD Range criteria
Total cholesterol 51 0 155.5 25.1 110.0–200.0 0.0%
(mg/dL) 51 14 170.3 28.1 95.0–226.0 0.0%
49 21 183.2 33.0 127.0–245.0 6.1%
40 42 186.2 35.1 107.0–279.0 5.0%
LDL-cholesterol 51 0 90.4 25.9 33.8–149.2 0.0%
(calc) (mg/dL) 51 14 100.0 25.4 40.8–158.2 0.0%
47 21 109.0 30.6 50.6–177.2 4.3%
39 42 111.6 34.2 43.8–214.0 7.7%
HDL-cholesterol 51 0 45.3 12.7 19.0–80.0 31.3%
(mg/dL) 51 14 47.8 12.5 28.0–79.0 27.5%
49 21 47.1 1.5 27.0–74.0 28.6%
40 42 51.8 13.8 31.0–87.0 17.5%
Non-HDL- 51 0 110.2 23.7 58–164 0.0%
cholesterol 51 14 122.5 26.7 58–175 0.0%
(mg/dL) 49 21 136.1 32.8 71–212 4.1%
39 42 134.4 34.5 67–229 5.1%
TotalHDL 51 0 3.64 0.97 2.02–5.89 —
cholesterol 51 14 3.74 0.96 2.25–5.77 —
ratio 49 21 4.11 1.22 2.27–8.31 —
39 42 3.80 1.05 2.23–6.29 —
Triglycerides 50 0 93.9 46.7 45.0–221.0 18.0%
(mg/dL) 50 14 109.7 50.2 50.0–244.0 16.0%
47 21 123.0 57.3 50.0–332.0 23.4%
40 42 106.8 57.1 40.0–288.0 15.0%
Glucose (mg/dL) 52 0 89.3 7.9 76.0–115.0 7.7%
52 14 91.5 7.5 71.0–110.5 9.6%
51 21 91.1 5.7 79.0–101.0 2.0%
43 42 89.2 5.7 74.0–101.5 2.3%
Insulin (U/mL) 50 0 6.73 3.01 2.00–16.10 2.0%
50 14 6.45 3.48 1.10–20.60 2.0%
47 21 6.66 3.37 2.00–15.40 2.1%
40 42 7.68 3.83 2.00–19.20 5.0%
Insulin resistance 50 0 1.51 0.74 0.42–4.05 —
(HOMA) 50 14 1.47 0.83 0.26–4.41 —
47 21 1.51 0.80 0.42–3.66 —
40 42 1.71 0.90 0.38–4.47 —
C-peptide 52 0 1.61 0.65 0.61–3.80 —
(ng/mL) 52 14 1.53 0.70 0.46–3.30 —
50 21 1.59 0.71 0.54–3.90 —
41 42 1.59 0.75 0.60–3.70 —
NCEP ATP III threshold levels: total cholesterol 240 mg/dL, LDL-c 160 mg/dL, HDL-c 40 (men) 50 
(women) mg/dL, non-HDL-c 	190 mg/dL, TG 150, glucose 100 mg/dL, insulin 15 U/mL.
lipoprotein parameters in the absence of weight
gain. Depending on the magnitude of the
NNRTI plus PI-induced increases in TG, TC,
LDL-c, HDL-c, the cumulative effects on
lipid/lipoprotein parameters may be pro-
atherogenic, and indicate that caution should
be exercised when dual PI-containing regimens
(e.g., ritonavir boosting) are prescribed.
The lipid/lipoprotein alterations observed
here are consistent with earlier reports in un-
infected volunteers showing 10-40% increases
in total- and HDL-cholesterol following short-
term exposure to efavirenz with NRTIs or in-
dinavir.42 They are also consistent with the
short-term metabolic effects of amprenavir-
based antiretroviral regimens on fasting serum
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TABLE 2. ALTERATIONS IN LIPID/LIPOPROTEIN AND GLUCOREGULATORY PARAMETERS AFTER EFAVIRENZ PLUS
AMPRENAVIR (DAY 14 VS. DAY 0), AFTER CONTINUED EFAVIRENZ AND AMPRENAVIR, PLUS 7 DAYS OF
A SECOND PI (DAY 21 VS. 14), AND AFTER DISCONTINUING ALL ARV MEDICATIONS (DAY 42 VS. 0)
Day 14 vs. 0 Day 21 vs. 14 Day 42 vs. 0
Measure N LSMa SEb 95% CIc N LSM SE 95% CI N LSM SE 95% CI
T-C 51 14.8 3.8 7.4, 22.3 49 13.1 3.8 5.6, 20.7 40 29.1 4.1 21.0, 37.2
LDL-C 51 9.6 3.5 2.8, 16.4 47 8.7 3.6 1.6, 15.7 39 20.1 3.8 12.6, 27.6
HDL-C 51 2.5 1.0 0.4, 4.6 49 0.8 1.1 2.9, 1.3 40 6.8 1.1 4.6, 9.1
TCHC 51 0.10 0.09 0.08, 0.28 49 0.37 0.09 0.19, 0.55 39 0.06 0.10 0.14, 0.26
TG 50 15.8 7.5 0.9, 30.6 47 17.7 7.7 2.6, 32.9 40 9.5 8.1 6.4, 25.5
GLU 52 2.26 1.04 0.20, 4.32 51 0.42 1.05 2.49, 1.65 43 0.29 1.11 2.47, 1.90
INS 50 0.28 0.42 1.11, 0.55 47 0.17 0.43 0.68, 1.02 40 1.04 0.45 0.14, 1.93
aLeast squares mean of change; bolded values are significant (95% CI does not include the value zero).
bAssociated standard error.
c95% confidence interval around least-square mean change; bolded if significant.
All units are mg/dL, except insulin (U/mL).
TABLE 3. PREDICTED CHANGES IN METABOLIC PARAMETERS BASED ON OBSERVED AMPRENAVIR AND EFAVIRENZ AUCS
Amprenavir AUC in plasma
(g  h/mL)a HDL-c, day 14b TCHC, day 14c TG, day 14d GLU, day 21e CPEP, day 14f
0.5 7.44 0.17 3.04 1.87 0.38
4.0 3.10 0.12 20.96 1.25 0.04
8.0 1.86 0.46 41.45 0.54 0.34
14.0 9.29 0.96 72.18 0.52 0.92
Efavirenz AUC in plasma
(g  h/mL)
20.0 0.64 — 35.78 —
38.0 2.29 — 24.79 —
170.0 14.34 — 55.83 —
aRepresentative plasma amprenavir AUCs were derived from A5043 as follows: 0.5 was the minimum AUC, 4.0
represents the median AUC on days 14 and 21, 8.0 represents the median AUC on day 0, and 14.0 represents the
maximum AUC on day 14. For efavirenz AUCs: 20.0, 38.0 and 170.0 represent the minimum, median and maximum
values obtained on A5043 subjects.
bHDL-cholesterol, mg/dL. The estimated regression equations were: (1) for changes on day 14, 19.43—(0.26*base-
line HDL–c)—1.24 (0.97*day 14 amprenavir AUC), and (2) for additional changes on day 21, 8.81—(0.23*baseline HDL-
c)  (0.09* day 14 efavirenz AUC). In generating predicted values, baseline median HDL-c (43.0) was used. (Baseline
values were predictive of day 14 changes from baseline.)
cRatio of totalHDL-cholesterol, change from baseline on day 14. The estimated regression equation was: 0.57—
(0.22*baseline TCHC)  (0.08*day 14 amprenavir AUC). Baseline median TCHC (3.57) was used.
dTriglycerides, change from baseline on day 14, mg/dL. The estimated regression equations were: (1) as a function
of amprenavir AUCs, 27.45—(0.34*baseline TG)  (5.12*day 14 amprenavir AUC), and (2) as a function of efavirenz
AUCs, 68.76—(0.26*baseline TG)—(0.61*day 14 efavirenz AUC). Baseline median TG (79.5) was used.
eBlood glucose, change from day 14 on day 21, mg/dL. The estimated regression equation was: 1.95—(0.18*day 14
amprenavir AUC). Baseline GLU, not a significant predictor, was not included as a model covariate.
fC-peptide, change from baseline on day 14, ng/mL. The estimated regression equation was: 0.09—(0.34*baseline
CPEP)  (0.10*day 14 amprenavir AUC). Baseline median CPEP (1.5) was used.
Predicted change in metabolic parameter (associated 95% confidence intervals)
lipid/lipoprotein levels, with modest effects on
glucose and insulin levels, in HIV-infected peo-
ple,43 and with long-term metabolic effects of
efavirenz-based regimens on fasting serum
lipid/lipoprotein levels in HIV-infected peo-
ple.44 In these latter two studies, 48 weeks of
antiretroviral therapy was associated with
weight and fat gain, and these may have con-
tributed to the development of dyslipidemia or
insulin resistance. In the present study, weight
changes were minimal and could not account
for the metabolic alterations observed, sug-
gesting that intrinsic pharmacokinetic-pharma-
codynamic effects mediated the metabolic al-
terations.
On day 14, when all subjects were exposed
to efavirenz plus amprenavir, higher plasma
amprenavir AUCs were associated with larger
increases in triglycerides, C-peptide and TCHC
ratio. In contrast, subjects with larger ampre-
navir AUCs tended to have smaller increases
in HDL-cholesterol (day 14) and in glucose
(day 21). For a hypothetical subject with a base-
line triglyceride of 79.5 mg/dL and an ampre-
navir AUC of 14.0 g/mL, our regression
model predicted a triglyceride increase of 72.2
mg/dL, resulting in an expected triglyceride
level of 152 mg/dL, which exceeds the NCEP
classification (TG 	150mg/dL). These findings
strongly suggest that pharmokinetic interac-
tions among ARV medications, and the result-
ing ‘boosted’ levels of certain ARV medica-
tions, in this case amprenavir, can adversely
alter lipid/lipoprotein levels. The findings fur-
ther suggest that ARV pharmacokinetic-phar-
macodynamic interactions can occur rapidly,
can dysregulate lipid/lipoprotein, and to a
lesser extent, glucose metabolism, can occur at
subtherapeutic doses of amprenavir, and may
augment the risk for cardiometabolic syn-
drome.
Significant elevations in total-, HDL-, and
LDL-cholesterol and insulin persisted 2–3
weeks after drug exposure, whereas triglyc-
erides and glucose returned to baseline levels
more quickly. The magnitude of elevation was
not associated with time since drug discontin-
uation. Triglyceride, but not total-cholesterol,
levels have been reported to return to baseline
in some but not all PI-to-NNRTI switch stud-
ies. Augmented cholesterol and lipoprotein
production rates, along with impairments in
cholesterol and lipoprotein clearance rates, are
responsible for dyslipidemia in HIV-infected
people, both before and after initiating ARV
therapy.45,46 Whether the persistent lipid/
lipoprotein changes noted here were due to
ARV pharmokinetic-pharmacodynamic inter-
actions and their effects on cholesterol-lipopro-
tein production and/or clearance rates is not
clear, but requires further investigation.
The largest cholesterol and triglycerides
changes from baseline were seen on day 21,
when subjects were taking efavirenz, ampre-
navir, and a second PI (in 4 of 5 arms). Poten-
tial explanations for the additional alterations
(day 21 vs. 14) in lipid/lipoprotein parameters
include (1) extended duration of efavirenz and
amprenavir exposure, (2) direct effects of the
added PI, or (3) increased amprenavir levels
(on some arms) secondary to the added PI. The
present study was neither designed nor pow-
ered to differentiate among these factors. In
particular, if direct effects due to second PIs
truly existed, it appears that they were either
obscured by arm differences in amprenavir lev-
els or undetectable due to small sample sizes.
It is interesting that although amprenavir
AUCs exhibited much wider variation on day
21, more of the day 14 metabolic changes were
associated with amprenavir levels.
In this short-term study, a prolonged phar-
macologic effect may have induced sustained
biochemical alterations. Alternately, prolonged
elimination of efavirenz may have contributed
to the metabolic changes observed. Clinically
and statistically significant changes on day 14
seem more likely due to 13 days of efavirenz
rather than 3 days of amprenavir dosing. The
longer half-life of efavirenz (50h)42 relative to
the other drugs suggests that it may have a role
in the persistence of metabolic alterations 2–3
weeks after simultaneous discontinuation of all
study drugs. The short-term effects of ampre-
navir on lipids and metabolic parameters
demonstrated during concurrent efavirenz ad-
ministration should be viewed in the context of
long-term studies of amprenavir without
efavirenz given. In one study of 455 HIV-in-
fected people,47 48 wks of amprenavir use was
associated with severe hypertriglyceridemia
(	750 mg/dL), hyperglycemia (	250 mg/dL),
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or hypercholesterolemia (	320 mg/dL) in only
5%, 1%, and 1% of the participants, respec-
tively. In a review of amprenavir safety data
from adult study treatment groups, median
values for triglyceride, glucose, and total-cho-
lesterol levels showed no clinically significant
changes over 64 weeks, although slight initial
increases in median total-cholesterol levels
were observed.48 In PRO3001, the incidence of
grade 3–4 increases in TG was 0% with ampre-
navir/lamivudine/zidovudine (n  111) and
1% with lamivudine/zidovudine (n  108).
There were some limitations. Healthy HIV-
seronegative men and women were enrolled to
examine the effects of select ARV medication
exposures without the potential confounders of
HIV-infection, comorbidities, and other ARV
drug classes. Thus, the complex clinical condi-
tion typical of HIV-1 infected patients is over-
simplified. Efavirenz and protease inhibitor
pharmacokinetic parameters were similar to
those that have been reported in HIV-infected
patients, and our findings provide a framework
for interpreting ARV-induced metabolic
changes in HIV-infected people. Currently, ri-
tonavir-boosted ARV regimens are used most
commonly. These were not a focus of the cur-
rent study (which was designed several years
ago). Future studies will examine the metabolic
alterations that occur with newer PIs (e.g.,
lopinavir, atazanavir) boosted by ritonavir.
CONCLUSION
In conclusion, pharmacokinetic and phar-
macodynamic drug interactions resulting
when efavirenz was combined with single or
dual PIs are complex, should be examined with
regard to individual medications, and may in-
duce elevations in serum lipid/lipoprotein lev-
els that are proatherogenic. Changes in serum
lipids noted during short-term treatment did
not return to baseline after drug discontinua-
tion, suggesting that a prolonged pharma-
cologic effect—possibly sustained, direct phar-
macologic action or delayed efavirenz elimina-
tion—needs to be examined further with 
dual-PI regimens that include ritonavir phar-
macokinetic enhancement, with and without
efavirenz.
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